TECENTRIQ (atezolizumab) Auz and Tom
Posted: Thu Nov 24, 2016 11:10 am
Thank to our member, we now have an information about the good response to another PD-L1 immunotherapy drug on a market - TECENTRIQ (atezolizumab) by Genentech, Roche's subsidiary.
The patient Auz from Toronto - Dx May 2015 at 19 yo is participating in a clinical trial ClinicalTrials.gov Identifier: NCT02458638
view here:
https://clinicaltrials.gov/ct2/show/NCT02458638
reposted from here:
http://www.cureasps.org/forum/viewtopic ... 9907#p9907
It is now approved for the advanced urothelial carcinoma (mUC) or non-small cell lung cancer (NSCLC) in US, but It could probably be prescribed for ASPS off label if there are no other treatment options available and based on a response our patient is having.
It is still preferable to get the drug on a trial versus off label if possible so the response is properly documented and the patient gets proper side effects care as they might be not that well known by now.
There is also pediatric arm open as a separate clinical trial:
ClinicalTrials.gov Identifier: NCT02541604
https://clinicaltrials.gov/ct2/show/study/NCT02541604
Also open in China and other countries.
There are also numerous combination trials open with this drugs but it is hard to say which one could be appropriate for ASPS in aim to improve its efficiency.
The patient Auz from Toronto - Dx May 2015 at 19 yo is participating in a clinical trial ClinicalTrials.gov Identifier: NCT02458638
view here:
https://clinicaltrials.gov/ct2/show/NCT02458638
reposted from here:
http://www.cureasps.org/forum/viewtopic ... 9907#p9907
It is now approved for the advanced urothelial carcinoma (mUC) or non-small cell lung cancer (NSCLC) in US, but It could probably be prescribed for ASPS off label if there are no other treatment options available and based on a response our patient is having.
It is still preferable to get the drug on a trial versus off label if possible so the response is properly documented and the patient gets proper side effects care as they might be not that well known by now.
There is also pediatric arm open as a separate clinical trial:
ClinicalTrials.gov Identifier: NCT02541604
https://clinicaltrials.gov/ct2/show/study/NCT02541604
Also open in China and other countries.
There are also numerous combination trials open with this drugs but it is hard to say which one could be appropriate for ASPS in aim to improve its efficiency.